

### **REMARKS**

The title of the application has been amended to more accurately reflect the subject matter of the claims. Upon the entry of the amendments as outlined above, claims 23 and 24 are pending in this application. Claims 1-18 were canceled in a preliminary amendment. Claims 19-20 submitted in the preliminary amendment and claims 21-22 of the originally-filed application have been canceled to correct numbering errors that apparently occurred in the preliminary amendment. New claim 23 is the same as claim 19 submitted in the preliminary amendment. New claim 24 is to further define the subject matter of the invention. The specific cancers recited in claim 24 are disclosed in the originally-filed application. Support for the claim can be found, for example, in paragraph 14 (cancer of the eye), paragraph 18 (carcinoma), paragraph 23 (retinoblastoma), paragraph 24 (ovarian cancer), paragraph 25 (breast cancer or prostate cancer), paragraph 26 (melanoma), paragraph 27 (bladder cancer), paragraph 29 (rhabdomyosarcoma, retinoblastoma, Ewing's sarcoma, neuroblastoma, osteosarcoma or blood-borne tumors), paragraph 30 (hemangioma), paragraph 31 (multiple small angioma, tumor of blood vessel or tumor of lymph vessel) or paragraph 92 (prostate cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, gliomas, hemangiomas, Kaposi's sarcoma, pancreatic cancer, retinoblastomas, melanomas, bladder cancer, rhabdomyosarcomas, retinoblastomas, Ewing's sarcoma, neuroblastomas, osteosarcoma, leukemia, cancer of the bone marrow, lung cancer, liver cancer, or peritoneal cancer). Accordingly, no new matter has been added by the amendment, and the entry is respectfully requested.

Applicants reserve the right to file one or more divisional, continuation, or continuation-in-part applications directed to the subject matter recited by the canceled claims, as well as any other subject matter disclosed in the application, which is not encompassed by the pending claims.

The Examiner appears to be referring to claims 19 and 20 submitted in the preliminary amendment as claims 18 and 19, respectively, in Office Action at pages 2-3. Claim 19 (in fact, claim 20) is rejected under 35 U.S.C. 112, first paragraph, as allegedly failing to meet enablement requirement, on the ground that the compounds disclosed in the specification have no pharmacological data regarding treatments for all types of cancers or tumors. (Office Action at pages 2-3). The Examiner suggests that the claim be limited to the specific cancers disclosed in the specification. (Office Action at page 3). Without


acquiescing to the Examiner's rejection, and solely in order to promote the progress of the present application, claims 19-20 have been canceled and new claim 24 recites specific cancers supported by the specification. The amendment renders the rejection moot. Accordingly, Applicants respectfully request that the rejection under 35 U.S.C. § 112, first paragraph be withdrawn.

### **Conclusion**

In view of the foregoing, Applicants believe that the claims as amended overcome rejections under 35 U.S.C. §112, and therefore are in condition for allowance. Reconsideration, entry of the above amendments, and allowance are respectfully requested. Should the Examiner not agree that all claims are allowable, a personal or telephonic interview is respectfully requested to discuss any remaining issues and to accelerate the allowance of the above-identified application.

Respectfully submitted,

Date October 13, 2004

  
\_\_\_\_\_  
Yeahsil Moon (Reg. No. 52,042)  
JONES DAY  
222 East 41<sup>st</sup> Street  
New York, NY 10017  
Tel. (212) 326-3778

For: Anthony M. Insogna (Reg. No. 35,203)  
JONES DAY  
12750 High Bluff Drive - Suite 300  
San Diego, CA 92130  
Tel. (858) 314-1200